Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults

Pharmacotherapy

Volumn 30, Issue 7, 2010, Pages 728-740

  Buckley, Mitchell S ^a   Feldman, Jeremy P ^b  

^a BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^b Arizona Pulmonary Specialists Ltd   (United States)

Author keywords

Critical illness; Epoprostenol; Inhalation; PAH; Pulmonary arterial hypertension

Indexed keywords

GLYCERYL TRINITRATE; MILRINONE; NITRIC OXIDE; PROSTACYCLIN; VASODILATOR AGENT;

CLINICAL TRIAL; CRITICALLY ILL PATIENT; HUMAN; LUNG PRESSURE; PULMONARY HYPERTENSION; REVIEW; ADULT; ARTERY; DRUG EFFECTS; HEART SURGERY; HEART TRANSPLANTATION; HEMODYNAMICS; HYPERTENSION; HYPERTENSION, PULMONARY; PULMONARY ARTERY; TREATMENT OUTCOME;

ADULT; ARTERIES; CARDIAC SURGICAL PROCEDURES; EPOPROSTENOL; HEART TRANSPLANTATION; HEMODYNAMICS; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; NITRIC OXIDE; PULMONARY ARTERY; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77954103049     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.7.728     Document Type: Review

References (65)

1. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:1527-38.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
3. Subramaniam K, Yared JP. Management of pulmonary hypertension in the operating room. Semin Cardiothorac Vasc Anesth 2007;11:119-36.
4. Via G, Braschi A. Pathophysiology of severe pulmonary hypertension in the critically ill patient. Minerva Anestesiol 2004;70:233-7. (Pubitemid 38931292)
5. Tsapenko MV, Tsapenko AV, Comfere TB, Mour GK, Mankad SV, Gajic O. Arterial pulmonary hypertension in noncardiac intensive care unit. Vasc Health Risk Manag 2008;4:1043-60.
6. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007;35:2037-50.
7. Costard-Jackle A, Hill I, Schroeder JS, Fowler MB. The influence of preoperative patient characteristics on early and late survival following cardiac transplantation. Circulation 1991;84(suppl III):III329-37.
8. Kirklin JK, Naftel DC, McGiffin DC, McVay RF, Blackstone EH, Karp RB. Analysis of morbid events and risk factors for death after cardiac transplantation. J Am Coll Cardiol 1988;11:917-24.
9. Murali S, Kormos RL, Uretsky BF, et al. Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J 1993;126:896-904.
10. Chen JM, Levin HR, Michler RE, Prusmack CJ, Rose EA, Aaronson KD. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg 1997;114:627-34.
11. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992;19:48-54.
12. Drakos SG, Kfoury AG, Gilbert EM, et al. Effect of reversible pulmonary hypertension on outcomes after heart transplantation. J Heart Lung Transplant 2007;26:319-23.
13. Chang PP, Longenecker JC, Wang NY, et al. Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality. J Heart Lung Transplant 2005;24:998-1007.
14. Butler J, Stankewicz MA, Wu J, et al. Pre-transplant reversibility pulmonary hypertension predicts higher risk for mortality after cardiac transplantation. J Heart Lung Transplant 2005;24:170-7.
15. Komai H, Adatia IT, Elliott MJ, de Leval MR, Haworth SG. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg 1993;106:473-8. (Pubitemid 23277619)
16. Downing SW, Edmunds LH. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992;54:1236-43.
17. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31:891-901.
18. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:S13-24.
19. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
20. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82.
21. Granton J, Moric J. Pulmonary vasodilators: treating the right ventricle. Anesthesiol Clin 2008;26:337-53.
22. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-28.
23. Wetzel RC. Aerosolized prostacyclin: in search of the ideal pulmonary vasodilator. Anesthesiology 1995;82:1315-17.
24. Bloch KD, Ichinose F, Roberts JD Jr, Zapol WM. Inhaled NO as a therapeutic agent. Cardiovasc Res 2007;75:339-48.
25. Girard C, Lehot JJ, Pannetier JC, Filley S, French P, Estanove S. Inhaled nitric oxide after mitral valve replacement in patients with chronic pulmonary artery hypertension. Anesthesiology 1992;77:880-3.
26. Lindberg L, Larsson A, Steen S, Olsson SG, Nordstrom L. Nitric oxide gives maximal response after coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1994;8:182-7.
27. Solina AR, Ginsberg SH, Papp D, et al. Dose response to nitric oxide in adult cardiac surgery patients. J Clin Anesth 2001;13:281-6.
28. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993;88(5 pt 1):2128-38. (Pubitemid 23326092)
29. Fierobe L, Brunet F, Dhainaut JF, et al. Effect of inhaled nitric oxide on right ventricular function in adult respiratory distress syndrome. Am J Respir Crit Care Med 1995;151:1414-19.
30. Gerlach H, Pappert K, Lewandowski K, Rossaint R, Falke KJ. Long-term inhalation with evaluated low doses of nitric oxide for selective improvement of oxygenation in patients with adult respiratory distress syndrome. Intensive Care Med 1993;19:443-9. (Pubitemid 24035327)
31. Lotti GA, Olivei MC, Palo A, Galbusera C, Veronesi R, Braschi A. Acute effects of inhaled nitric oxide in adult respiratory distress syndrome. Eur Respir J 1998;12:1164-71.
32. Rossaint R, Slama K, Steudel W, et al. Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome. Intensive Care Med 1995;21:197-203.
33. George I, Xydas S, Topkara VK, et al. Clinical indication for use and outcomes after inhaled nitric oxide therapy. Ann Thorac Surg 2006;82:2161-9.
34. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;153:991-6.
35. 2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996;154:1671-7.
36. Bhorade S, Christenson J, O'Connor M, Lavoie A, Pohlman A, Hall JB. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Resp Crit Care Med 1999;159:571-9. (Pubitemid 29084883)
37. Yurtseven N, Karaca P, Kaplan M, et al. Effect of nitroglycerin inhalation on patients with pulmonary hypertension undergoing mitral valve replacement surgery. Anesthesiology 2003;99:855-8.
38. Sablotzki A, Starzmann W, Scheubel R, Grond S, Czeslick EG. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can J Anaesth 2005;52:1076-83. (Pubitemid 43192564)
39. Domenighetti G, Stricker H, Waldispuehl B. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit Care Med 2001;29:57-62. (Pubitemid 32125775)
40. van Heerden PV, Blythe D, Webb SA. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS: a pilot study. Anaesth Intensive Care 1996;24:564-8. (Pubitemid 26377305)
41. van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000;117:819-27. (Pubitemid 30152226)
42. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W. Aerosolized prostacyclin in adult respiratory distress syndrome. Lancet 1993;342:961-2.
43. Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W. Effects of aerosolized prostacyclin in severe pneumonia: impact of fibrosis. Am J Respir Crit Care Med 1995;151:724-30.
44. Haraldsson A, Kieler-Jensen N, Ricksten SE. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplant: a pharmacodynamic study. J Cardiothorac Vasc Anesth 1996;10:864-8.
45. Haraldsson A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001;93:1439-45. (Pubitemid 33111666)
46. Haché M, Denault A, Bélisle S, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. J Thorac Cardiovasc Surg 2003;125:642-9.
47. Fattouch K, Sbraga F, Bianco G, et al. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg 2005;20:171-6.
48. Fattouch K, Sbraga F, Sampognaro R, et al. Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. J Cardiovasc Med (Hagerstown) 2006;7:119-23.
49. De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004;127:1058-67.
50. Della Rocca G, Coccia C, Costa MG, et al. Inhaled aersolized prostacyclin and pulmonary hypertension during anesthesia for lung transplantation. Transplant Proc 2001;33:1634-6.
51. Della Rocca G, Coccia C, Pompei L, et al. Hemodynamic and oxygenation changes of combined therapy with inhaled nitric oxide and inhaled aerosolized prostacyclin. J Cardiothorac Vasc Anesth 2001;15:224-7.
52. Eichelbrönner O, Reinelt H, Wiedeck H, et al. Aerosolized prostacyclin and inhaled nitric oxide in septic shock: different effects on splanchnic oxygenation? Intensive Care Med 1996;22:880-7.
53. Bein T, Metz C, Keyl C, Sendtner E, Pfeifer M. Cardiovascular and pulmonary effects of aerosolized prostacyclin administration in severe respiratory failure using a ventilator nebulization system. J Cardiovasc Pharmacol 1996;27:583-6.
54. Haché M, Denault AY, Bélisle S, et al. Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit. Can J Anaesth 2001;48:924-9. (Pubitemid 33150289)
55. Forrest IA, Small T, Corris PA. Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls. Clin Sci (Lond) 1999;97:99-102.
56. Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt U, Bergh CH, Ricksten SE. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 1998;114:780-6.
57. Mikhail G, Gibbs J, Richardson M, et al. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997;18:1499-504.
58. Olschewski H, Walmrath D, Schermuly R, Ghofrani HA, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124:820-4. (Pubitemid 26128412)
59. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999;160:600-7.
60. Weston MW, Isaac BF, Crain C. The use of inhaled prostacyclin in nitroprusside-resistant pulmonary artery hypertension. J Heart Lung Transplant 2001;20:1340-4.
61. Coates AL, Ho SL. Drug administration by jet nebulization. Pediatr Pulmonol 1998;26:412-23.
62. Fink JB. Aerosol device selection: evidence to practice. Respir Care 2000;45:874-85.
63. Newman SP. Aerosol deposition considerations in inhalation therapy. Chest 1985;88(2 suppl):S152-60.
64. Thomas SH, O'Doherty MJ, Fidler HM, Page CJ, Treacher DF, Nunan TO. Pulmonary deposition of a nebulized aerosol during mechanical ventilation. Thorax 1993;48:154-9.
65. Haraldsson A, Kieler-Jensen N, Wadenvik H, Ricksten SE. Inhaled prostacyclin and platelet function after cardiac surgery and cardiopulmonary bypass. Intensive Care Med 2000;26:188-94. (Pubitemid 30186593)